Comparative Pharmacology
Head-to-head clinical analysis: FLORONE versus ILUVIEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLORONE versus ILUVIEN.
FLORONE vs ILUVIEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; induces phospholipase A2 inhibitory proteins (lipocortins), which suppress release of arachidonic acid and subsequent prostaglandin/leukotriene synthesis; also suppresses cytokine production and immune cell migration.
Fluocinolone acetonide, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. It also inhibits cytokine production and endothelial cell adhesion molecule expression.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum use: 45 g/week.
Intravitreal implant containing 0.19 mg fluocinolone acetonide, designed to release drug over approximately 36 months. Administered as a single injection into the vitreous cavity of the eye.
None Documented
None Documented
Terminal elimination half-life of approximately 2-3 hours; clinical context: duration of action may extend beyond half-life due to tissue binding.
Intravitreal terminal half-life of fluocinolone acetonide from the Iluvien implant is approximately 30 months (range 18-36 months), providing sustained release over 36 months in the vitreous cavity.
Renal (approximately 80% as metabolites, <5% unchanged), biliary/fecal (remainder).
Fluocinolone acetonide is primarily eliminated via hepatic metabolism and subsequent fecal/biliary excretion. Approximately 50-70% of a dose is excreted in feces as metabolites, with less than 20% recovered in urine as unchanged drug or metabolites.
Category C
Category C
Corticosteroid
Corticosteroid